Iris Melanoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Iris Melanoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT03809585

Observational Study of Iris Tumors

This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from h…

United States100 participantsStarted 2018-06-20

All recent trials (48 shown)

CompletedPhase 1

NCT05628883

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes \[TIL\]…

United States17 participantsStarted 2022-11-22

Treatment: TBio-4101, Cyclophosphamide

Active — Not RecruitingPhase 2

NCT02068586

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other par…

United States210 participantsStarted 2014-11-19

Treatment: Sunitinib, Valproic Acid

Iris Melanoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Observational Study of Iris Tumors

All recent trials (48 shown)

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Observational Study of Iris Tumors

All recent trials (48 shown)

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Met…

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class…

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Mel…

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Validation of a Molecular Prognostic Test for Eye Melanoma

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Vaccine Therapy in Treating Patients With Advanced Melanoma

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Can…